Yue-Ting Wang

Dr. Yue-Ting Wang


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 July 2024 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
YWYue-Ting Wang
Yue-Ting Wang
EPEdward Price
Edward Price
MFMei Feng
Mei Feng
JHJason Hulen
Jason Hulen
SDStella Doktor
Stella Doktor
GJGary J. Jenkins
Gary J. Jenkins

1 February 2023 in Bioanalysis
Verified
Journal Article
Closed access
YWYue-Ting Wang
Yue-Ting Wang
EMEstelle M Maes
Estelle M Maes
LHLance Heinle
Lance Heinle
KRKenneth Ruterbories
Kenneth Ruterbories
SDStella Doktor
Stella Doktor
GJGary J Jenkins
Gary J Jenkins
While bioanalytical outsourcing is widely adopted in the pharmaceutical industry, AbbVie is one of the few large biopharmaceutical companies having an internal bioanalytical unit to support nearly ...

14 May 2025 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
EPEdward Price
Edward Price
MDMatthieu Dagommer
Matthieu Dagommer
MTMattson Thieme
Mattson Thieme
RHRichard Hong
Richard Hong
JKJ. Cory Kalvass
J. Cory Kalvass
DDDavid DeGoey
David DeGoey

Verified
Journal Article
Open access
PDF file
SLSarah May Lloyd
Sarah May Lloyd
ESElizabeth Sande
Elizabeth Sande
KRKenneth J Ruterbories
Kenneth J Ruterbories
SOStephen O'Brien
Stephen O'Brien
YWYue-Ting Wang
Yue-Ting Wang
QJQin C Ji
Qin C Ji
Alterations to post-translational crosslinking modifications in the extracellular matrix (ECM) are known to drive the pathogenesis of fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Thus, the methodology for measuring crosslinking dynamics is valuable for understanding disease progression. The existing crosslinking analysis sample preparation and liquid chromatography tandem mass spectrometry (LC-MS/MS) methods are typically labor-intensive and time-consuming which limits throughput. We, therefore, developed a rapid approach minimizing specialized equipment and hands-on time. The LC-MS/MS sample analysis time was reduced to two minutes per sample. We then improved the analytical integrity of the method by developing a novel surrogate matrix approach for the dihydroxylysinonorleucine (DHLNL) crosslink. By modifying sample preparation, we prepared a tissue-based surrogate matrix with undetectable levels of endogenous DHLNL, providing a strategy for quantifying this crosslink with a more relevant standard matrix. We then applied this rapid methodology to evaluating crosslinking in lung fibrosis. We showed an increase in DHLNL in human IPF lung relative to healthy donors, as well as in a fibrotic mouse model. Finally, we demonstrated that this increase in DHLNL could be mitigated with an anti-fibrotic compound, suggesting that this assay has potential for evaluating pharmaceutical compound efficacy.

13 December 2024 in Drug Metabolism and Disposition
Verified
Journal Article
Closed access
DKDavid A. Kukla
David A. Kukla
JSJulia Annette Schulz
Julia Annette Schulz
PLPaul R. Lesniak
Paul R. Lesniak
ESElizabeth Sande
Elizabeth Sande
YWYue-Ting Wang
Yue-Ting Wang
DSDavid M. Stresser
David M. Stresser

25 May 2026 in Drug Metabolism Reviews
Verified
Journal Article
Closed access
LCLionel Cheruzel
Lionel Cheruzel
UAUpendra A. Argikar
Upendra A. Argikar
PBPietro Brunetti
Pietro Brunetti
Maria ChatzopoulouMaria Chatzopoulou
Maria Chatzopoulou
LCLuying Chen
Luying Chen
CWCaroline Wei
Caroline Wei